Thursday, 8 December 2016

(NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels

(NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)